Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06541639
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-29
Brief Title:
EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Dose Escalation and Expansion Study to Evaluate the Safety Tolerability Immunogenicity and Initial Efficacy of EVM16 Injection as a Single and Combination With Tislelizumab in Subjects With Advanced or Recurrent Solid Tumors
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to learn the side effects safety and effect of a tumor vaccine EVM16 alone or in combined with an anti-PD-1 antibody tislelizumab This clinical trial will include solid tumor patients who failed standard treatment
The main questions to answer are
Safety of EVM16 Suitable dose of EVM16 Effects of EVM16 combined with tislelizumab
The main questions to answer are
Safety of EVM16 Suitable dose of EVM16 Effects of EVM16 combined with tislelizumab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None